Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases... Show more
The Moving Average Convergence Divergence (MACD) for ARGX turned positive on June 27, 2025. Looking at past instances where ARGX's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ARGX's RSI Indicator exited the oversold zone, of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 61 cases where ARGX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
ARGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on June 16, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on ARGX as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
ARGX moved below its 50-day moving average on June 13, 2025 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for ARGX moved below the 200-day moving average on May 30, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ARGX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The Aroon Indicator for ARGX entered a downward trend on June 27, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ARGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.219) is normal, around the industry mean (16.366). P/E Ratio (34.153) is within average values for comparable stocks, (58.189). ARGX's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.309). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (14.493) is also within normal values, averaging (252.247).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
a manufacturer of antibody-based medicines
Industry Biotechnology
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
FIAT | 3.41 | 0.16 | +4.92% |
YieldMax Short COIN Option Inc Strgy ETF | |||
DUHP | 35.29 | 0.14 | +0.40% |
Dimensional US High Profitability ETF | |||
HYHG | 64.83 | 0.19 | +0.29% |
ProShares High Yield—Interest Rate Hdgd | |||
ALTY | 11.63 | -0.01 | -0.09% |
Global X Alternative Income ETF | |||
PPH | 87.47 | -0.46 | -0.52% |
VanEck Pharmaceutical ETF |
A.I.dvisor indicates that over the last year, ARGX has been loosely correlated with ALNY. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if ARGX jumps, then ALNY could also see price increases.
Ticker / NAME | Correlation To ARGX | 1D Price Change % | ||
---|---|---|---|---|
ARGX | 100% | +0.02% | ||
ALNY - ARGX | 50% Loosely correlated | +1.55% | ||
IONS - ARGX | 45% Loosely correlated | +0.05% | ||
MTVA - ARGX | 43% Loosely correlated | -7.35% | ||
ROIV - ARGX | 43% Loosely correlated | -1.81% | ||
BLUE - ARGX | 40% Loosely correlated | N/A | ||
More |